Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma.

Cancers (Basel) · 2025 · PMC12691117 · PMID 41375071

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In patients with viral HCC (HBV or HCV), the subgroup analysis showed a trend toward a better outcome, suggesting that nonviral HCC may benefit less from immunotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.